|
|
Our Scientific Advisory Board
members as of July 2006 are as follows (listed alphabetically):
| John H. Abeles, MD |
John H. Abeles, M.D. joined the Scientific
Advisory Board of CombiMatrix in 2006. Dr. Abeles practiced Medicine in
London, before joining the Pharmaceutical Industry as a Senior Medical
Executive, with Pfizer, Inc., Sterling Drug, and Revlon Health Care.
From 1975 until 1980, he was a healthcare analyst with Kidder Peabody
and later formed MedVest Inc., a healthcare consulting firm. Since
1992, Dr. Abeles has been a Founder and investor in several investment
funds for both venture capital and public equities, whose investments
were centered around healthcare and medical equipment companies. He
also presently serves as a Managing Member of a New York based
investment fund focused on healthcare investments.
Dr. Abeles presently serves on the board of
directors for I-Flow Corporation (Nasdaq: IFLO), DUSA Pharmaceuticals
(Nasdaq: DUSA), CytoCore, Inc. (Nasdaq: MCDG) and Oryx Technology
(Nasdaq: ORYX). Dr. Abeles also serves as an Advisory Board Member of
the College of Chemistry, University of California, Berkeley, and is on
the Advisory Board of the Higuchi BioSciences Institute at the
University of Kansas.
Dr. Abeles received his Medical degree as
well as a degree in Pharmacology from the University of Birmingham,
England, in 1969. He is a Fellow of the Royal Society of Medicine,
London.
|
Shane
Grey, Ph. D.
GARVAN INSTITUTE OF MEDICAL
RESEARCH |
Dr. Grey was awarded his Ph.D. in 1995 from
Monash University where he characterized a novel cellular signaling
pathway regulating the human inflammatory response. Dr. Grey was then
recruited to the Novartis Center for Immunobiology in Boston where he
conducted his post-doctoral training in the areas of human immunology,
gene therapy, and transplantation.
Dr. Shane T. Grey was appointed Assistant Professor in Surgery at
Harvard Medical School’s Department of Surgery in 2001. Dr. Grey's
research focused on utilizing novel, state-of-the-art gene-based
therapies to treat important inflammatory diseases. This includes the
treatment of autoimmune deficiencies and other conditions such as
diabetes mellitus, a significant cause of suffering in our present day
community.
Dr. Grey currently sits on invited review boards for national and
international funding agencies and scientific journals. These include
the Juvenile Diabetes Foundation International, the National Health and
Medical Research Council of Australia, and journals including Journal
of Immunology and Immunology Today. He has been awarded the Juvenile
Diabetes Foundations internationally acclaimed Career Development
Award. This 750,000 (USD) research prize is awarded each year to
eminent scientists in the field of Type I diabetes research. This was
awarded to Dr Grey for his outstanding work in diabetes and to promote
development of his novel gene-based therapeutics to treat Type I
diabetes mellitus. In August 2003, Dr. Grey was awarded the “BioFirst
Award,” a prize given to only two internationally recognized scientists
each year to recruit and promote biotechnology research in Australia.
In August of 2004, Dr. Grey moved his research to the prestigious,
internationally recognized Garvan Institute of Medical Research in
Sydney Australia www.garvan.org.au. This institute
is a leader in gene-based medical research, promoting integrated
disease focused research that aims to discover the molecular basis for
disease.
|
| Mark
A. Kay, MD, Ph.D. STANFORD UNIVERSITY SCHOOL
OF MEDICINE |
Dr. Kay’s areas of specialty include work
in RNAi, gene therapy, nucleic-acid drug delivery, and viral
inhibition. He was the first to develop and demonstrate the efficacy of
siRNA in mammals, and his work on the use of siRNA to inhibit hepatitis
B is considered a seminal step in the advancement of this technology.
He and his laboratory at the Stanford University School of Medicine are
devoted to research on methods for controlling gene expression levels
as a means to treat disease. Current emphasis is on hemophilia, human
hepatitis virus infection, and diabetes, but the techniques are widely
applicable to a large number of other diseases. For hemophilia, the
approaches are currently in Phase I/II trials. For hepatitis B and C,
they have developed RNAi approaches in animal models and are developing
a therapy suitable for humans.
Dr. Kay is Professor, Departments of Pediatrics and Genetics, and
Director, Program in Human Gene Therapy, at the Stanford University
School of Medicine. Dr. Kay is one of the founders and currently the
Vice President of the American Society of Gene Therapy. Prior to that,
from 1993 to 1998, he was in the Department of Medicine at the
University of Washington. Dr. Kay completed his internship and
residency in 1990 and then did postdoctoral work in gene therapy from
1990 to 1993 at Baylor College of Medicine. Dr. Kay received a B.S.
degree from Michigan State University, and a Ph.D. and a M.D. from Case
Western Reserve University.
He is an author of over 100 articles, manuscripts, and book chapters, a
frequently invited lecturer, and the recipient of several honors
including, in 2000, the E. Mead Johnson Award for Pediatric Researcher
of the Year and the National Hemophilia Foundation Researcher of the
Year. |
F.
Mark Modzelewski
THE BENET GROUP
Founder and Principal |
F. Mark Modzelewski is Founder and
Principal of the Benet Group which helps develop nanotechnology
ventures. He is also the Founder of The NanoBusiness Alliance (www.nanobusiness.org).
The Alliance's mission is to create a collective voice for the emerging
small tech industry, and develop a range of initiatives to support and
strengthen the nanotechnology business community. This includes
research and education, public policy, public awareness and relations,
and industry support and development efforts.
Mark is also a member of the Nanotechnology Technical Advisory Group to
President Bush's Council of Advisors on Science and Technology (PCAST).
He is among the most well known figures in the nanotech field and was
recently recognized by Forbes Magazine as one of nanotech's top 5
"powerbrokers" and received a Small Times Best of Small Tech Awards. He
is a finalist for this year's Fortune Magazine "40 Under 40." Mark has
testified before the US Senate on nanotechnology funding, investment,
technology transfer, and global competition. He also developed
partnerships for the Alliance with Deloitte & Touche, Penton
Media, Nissho Iwai and others to develop reports, events, mentor
start-ups, and enter new markets. He also structured affiliate
organizations and regional nanobusiness "hubs" in the EU, Canada,
Israel, and a dozen US states.
Mark has lectured at numerous global technology and investor
conferences, leading think tanks, as well as briefing the White House,
US Dept. of Commerce, NSF, Congress, the Federal Reserve's Financial
Markets retreat, global Fortune 500 companies, and a multitude of
foreign government agencies.
Mark was previously an appointee in the Clinton Administration, which
he served as Special Assistant to Sec. Henry Cisneros at HUD and Sec.
Dan Glickman of USDA. He is a graduate of the University of Denver
College of Law and Boston University. |
Camran
Nezhat, MD,
FACOG, FACS
STANFORD UNIVERSITY SCHOOL
OF MEDICINE |
In the late 1970's, Dr. Camran Nezhat
introduced a technique that would revolutionize modern-day abdominal,
pelvic, and chest surgery. By attaching a video camera to a
laparoscope, he started to operate from a comfortable, upright
position, watching the TV monitors, rather than bent over, peering with
one eye through the lens of a scope. By placing monitors around the
operating room, the entire staff could now observe and participate in
the procedure. This evolved into the techniques known now as
Videolaparoscopy and Video-Assisted Surgery.
The surgical techniques of Video laparoscopy require only a few small
incisions, dramatically reducing pain and recovery time compared to
earlier, conventional open surgery (laparotomy), in which very large
incisions are generally required. In addition, through sharing his
expertise with other surgical specialists, Dr. Nezhat has been
instrumental in assisting with the adaptation and advancement of
minimally invasive surgery for such disciplines as thoracic, urologic,
neurological, gastroenterological, and other general surgeries. By
constantly seeking to perfect surgery, and to minimize discomfort and
complications for patients, he has gone on to perform and develop many
other innovative surgeries laparoscopically for the first time, some of
which were previously considered impossible. |
Roberto
Rosenkranz, Ph.D.
ROXRO PHARMA, LLC
Chairman and CEO |
Chairman and CEO Roberto Rosenkranz, Ph.D.,
M.B.A, co-founded Roxro Pharma, LLC. Dr. Rosenkranz’ experience in the
pharmaceutical industry spans nearly 20 years, encompassing both
science and business. He held positions in pharmacology, new product
development, market research, sales, managed care, and business
development at Syntex Corporation. He then served as Director of
Business Operations for Roche Laboratories. Most recently, he was
President and Chief Operating Officer of Scios Inc., a public
biopharmaceutical company. Dr. Rosenkranz has served on the board of
directors of both public and private companies, including Gemini
Genomics PLC, prior to its merger with Sequenom, Inc. He currently
serves on the board of directors of Pherin Pharmaceuticals. Dr.
Rosenkranz holds a B.A. in psychology from Stanford University, a Ph.D.
in pharmacology and toxicology from the University of California at
Davis, and an M.B.A. from Santa Clara University. He is the author of
over 70 scientific papers and abstracts, and holds six patents. |
Roger
L. Whiting, Ph.D.
ROXRO PHARMA, LLC
President & Chief Science Officer
|
Roger L. Whiting, Ph.D., is a founder and,
since October 1999, the President and Chief Scientific Officer of Roxro
Pharma LLC, a pharmaceutical company. From July 1995 to September 1999,
Dr. Whiting was the Senior Vice President of the Neurobiology Business
Unit of Roche Bioscience, a division of Syntex (U.S.A.) Inc., a
pharmaceutical research company. Dr. Whiting received a bachelor's
degree from the University of Bradford, UK and his Ph.D. from Aston
University, UK. |
|
ORDER 
